MERCURY BIO
Live / Registered — Registered (as of 04 Mar 2025)
What this means for you
Registered since 04 Mar 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98602178
- Registration number
- 7714747
- Mark type
- Stylized text
- Filed
- 14 Jun 2024
- Published for opposition
- 14 Jan 2025
- Registered
- 04 Mar 2025
- Attorney of record
- David S. Kerr
Goods and services
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, yeast derived extracellular vesicle-based delivery systems for pharmaceuticals, therapeutics, and biologics; Research and development in the fields of pharmaceuticals, therapeutics, and biologics, namely, development of humanized yeast extracellular vesicles delivery systems for pharmaceuticals, therapeutics, and biologics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics; Medical research and development in the field of molecular biology, genetic engineering, drug delivery, and bioinformatics, namely genetically engineering yeast cells to produce extracellular vesicles for delivery of pharmaceuticals, therapeutics, and biologics; Bioinformatics, namely genetically engineering yeast cells to produce humanized extracellular vesicles delivery of for pharmaceuticals, therapeutics, and biologics; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery systems for therapeutic compounds for the treatment of viral pathogens, cancer and inherited disorder in humans; Research and development of delivery systems for therapeutic compounds, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic compounds; Research and development of delivery systems for therapeutic nucleic acids, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic nucleic acids, namely, RNA; Research and development of delivery systems for therapeutic peptides, namely, yeast-derived extracellular vesicle-based drug delivery of therapeutic peptides; Research and development of delivery systems for gene-editing proteins, namely, yeast-derived extracellular vesicle-based drug delivery of gene-editing proteins; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for vaccines; Research and development of delivery systems for vaccines, namely, yeast-derived extracellular vesicle-based drug delivery systems for pharmaceutical compounds; Research and development of the production of extracellular vesicles for therapeutic uses, namely, yeast-derived extracellular vesicles for therapeutic uses; Research and development of new biological products for therapeutic use; Design and development of nucleic acids, proteins, enzymes, and drug compounds for use in pharmaceuticals, biotechnology, medical, and diagnostic applications; and Design and development of loading systems to load nucleic acids, proteins, enzymes, and drug compounds into yeast-derived extracellular vesicles for therapeutic uses
Owner
- Mercury Bio, Inc., Santa Fe, NM, US
- Mercury Bio, Inc., Santa Fe, NM, US
- Mercury Bio, Inc., Santa Fe, NM, US
Prosecution history
- 04 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 04 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jan 2025 — PUBLISHED FOR OPPOSITION
- 08 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Dec 2024 — EXAMINER'S AMENDMENT ENTERED
- 20 Dec 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 20 Dec 2024 — EXAMINERS AMENDMENT E-MAILED
- 20 Dec 2024 — EXAMINERS AMENDMENT -WRITTEN
- 19 Dec 2024 — ASSIGNED TO EXAMINER
- 14 Jun 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 14 Jun 2024 — NEW APPLICATION ENTERED